Evaluation of uptake and transport of ultrasmall superparamagnetic iron oxide nanoparticles by human brain-derived endothelial cells

Papers of special note have been highlighted as: ▪ of interest

References

• 1  Arruebo M, Fernández-Pacheco R, Ibarra MR, Santamaria J. Magnetic nanoparticles for drug delivery. Nano Today2,22–32 (2007).
  Google Scholar
• 2  Juillerat-Jeanneret L. The targeted delivery of cancer drugs across the blood–brain barrier: chemical modifications of drugs or drug-nanoparticles? Drug Discov. Today13,1099–1106 (2008).
  Medline CASGoogle Scholar
• 3  Weinstein JS, Varallyay CG, Dosa E et al. Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review. J. Cereb. Blood Flow Metab.30,15–35 (2010).
  Medline CASGoogle Scholar
• 4  Bhaskar S, Tian F, Stoeger T et al. Multifunctional nanocarriers for diagnostics, drug delivery and targeted treatment across blood–brain barrier: perspectives on tracking and neuroimaging. Part Fibre Toxicol.7,3 (2010).▪ Extensive review of the characteristics of nanoparticles as therapeutics for the brain.
  MedlineGoogle Scholar
• 5  Verma A, Stellacci F. Effect of surface properties on nanoparticle–cell interactions. Small6,12–21 (2010).
  Medline CASGoogle Scholar
• 6  Hillaireau H, Couvreur P. Nanocarriers’ entry into the cell: relevance to drug delivery. Cell. Mol. Life Sci.66,2873–2896 (2009).
  Medline CASGoogle Scholar
• 7  Nel A, Xia T, Mädler L, Li N. Toxic potential of materials at the nanolevel. Science311(5761),622–627 (2006).
  Medline CASGoogle Scholar
• 8  Xia T, Kovochich M, Brant J et al. Comparison of the abilities of ambient and manufactured nanoparticles to induce cellular toxicity according to an oxidative stress paradigm. Nano Lett.6,1794–1807 (2006).
  Medline CASGoogle Scholar
• 9  Møller P, Jacobsen NR, Folkmann JK et al. Role of oxidative damage in toxicity of particulates. Free Radical Res.44,1–46 (2010).▪ Extensive review of the cell oxidative stress reaction to particulate materials.
  Medline CASGoogle Scholar
• 10  Naqvi S, Samim M, Abdin M et al. Concentration-dependent toxicity of iron oxide nanoparticles mediated by increased oxidative stress. Int. J. Nanomed.5,983–989 (2010).
  Medline CASGoogle Scholar
• 11  Petri-Fink A, Chastellain M, Juillerat-Jeanneret L, Ferrari A, Hofmann H. Development of functionalized superparamagnetic iron oxide nanoparticles for interaction with human cancer cells. Biomaterials26,2685–2694 (2005).
  Medline CASGoogle Scholar
• 12  Cengelli F, Maysinger D, Tschuddi-Monnet F et al. Interaction of functionalized superparamagnetic iron oxide nanoparticles with brain structures. J. Pharm. Exp. Ther.318,108–116 (2006).
  Medline CASGoogle Scholar
• 13  Hanessian S, Grzyb JA, Cengelli F, Juillerat-Jeanneret L. Synthesis of chemically functionalized superparamagnetic nanoparticles as delivery vectors for chemotherapeutic drugs. Bioorg. Med. Chem.16,2921–2931 (2008).
  Medline CASGoogle Scholar
• 14  Cengelli F, Grzyb JA, Montoro A, Hofmann H, Hanessian S, Juillerat-Jeanneret L. Surface-functionalized ultrasmall superparamagnetic nanoparticles as magnetic delivery vectors for camptothecin. ChemMedChem4,988–997 (2009).
  Medline CASGoogle Scholar
• 15  Petri-Fink A, Steitz B, Finka A, Salaklang J, Hofmann H. Effect of cell media on polymer coated superparamagnetic iron oxide nanoparticles (SPIONs): colloidal stability, cytotoxicity, and cellular uptake studies. Eur. J. Pharm. Biopharm.68,129–137 (2008).
  Medline CASGoogle Scholar
• 16  Chastellain M, Petri A, Gupta A, Rao KV, Hofmann H. Superparamagnetic silica-iron oxide nanocomposites for application in hyperthermia. Adv. Eng. Mater.6,235–241 (2004).
  CASGoogle Scholar
• 17  Schaller V, Kräling U, Rusu C et al. Motion of nanometer sized magnetic particles in a magnetic field gradient. J. Appl. Phys.104,093918 (2008).
  Google Scholar
• 18  Kamau Chapman S, Hassa PO, Steitz B et al. Enhancement of the efficiency of non-viral gene delivery by application of pulsed magnetic field. Nucleic Acids Res.34,e40 (2006).
  MedlineGoogle Scholar
• 19  Zara GP, Cavalli R, Bargoni A, Fundaro A, Vighetto D, Gasco MR. Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: pharmacokinetics and distribution of doxorubicin in brain and other tissues. J. Drug Target.10,327–335 (2002).
  Medline CASGoogle Scholar
• 20  Gan CW, Feng SS. Transferrin-conjugated nanoparticles of poly(lactide)-D-α-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood–brain barrier. Biomaterials31,7748–7757 (2010).
  Medline CASGoogle Scholar
• 21  Liu Y, Li J, Shao K et al. A leptin derived 30-amino-acid peptide modified pegylated poly- l -lysine dendrigraft for brain targeted gene delivery. Biomaterials31,5246–5257 (2010).
  Medline CASGoogle Scholar
• 22  Tosi G, Vergoni AV, Ruozi B et al. Sialic acid and gylycopeptides conjugated PLGA nanoparticles for central nervous system targeting: in vivo pharmacological evidence and biodistribution. J. Control Release145,49–57 (2010).
  Medline CASGoogle Scholar
• 23  Huang R, Ke W, Han L et al. Brain-targeting mechanisms of lactoferrin-modified DNA-loaded nanoparticles. J. Cereb. Blood Flow Metab.29,1914–1923 (2009).
  Medline CASGoogle Scholar
• 24  Kreuter J, Shamenko D, Petrov V et al. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood–brain barrier. J. Drug Target.10,317–325 (2002).
  Medline CASGoogle Scholar
• 25  Kurakhmaeva KB, Djindjikhashvili IA, Petrov VE et al. Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles. J. Drug Target.17,564–574 (2009).
  Medline CASGoogle Scholar
• 26  Ambruosi A, Gelperina S, Khalansky A, Tanski S, Theisen A, Kreuter J. Influence of surfactants, polymer and doxorubicin loading on the anti-tumour effect of poly(butyl cyanoacrylate) nanoparticles in a rat glioma model. J. Microencaps.23,582–592 (2006).
  Medline CASGoogle Scholar
• 27  Gelperina S, Khalansky A, Skidan IN et al. Toxicolological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma. Toxicol. Lett.126,131–141 (2002).
  Medline CASGoogle Scholar
• 28  Sarin H, Kanevsky AS, Wu H et al. Effective transvascular delivery of nanoparticles across the blood–brain tumor barrier into malignant glioma cells. J. Transl. Med.6,80–95 (2008).
  MedlineGoogle Scholar
• 29  Veiseh O, Sun C, Fang C et al. Specific targeting of brain tumors with an optical/magnetic resonance imaging nanoprobe across the blood–brain barrier. Cancer Res.69,6200–6207 (2009).
  Medline CASGoogle Scholar
• 30  Ku S, Yan F, Wang Y, Sun Y, Yang N, Ye L. The blood–brain barrier penetration and distribution of PEGylated fluorescein-doped magnetic silica nanoparticles in rat brain. Biochem. Biophys. Res. Commun.394,871–876 (2010).
  Medline CASGoogle Scholar
• 31  Chang J, Jallouli Y, Kroubi M, Yuan XB et al. Characterization of endocytosis of transferrin-coated PLGA nanoparticles by the blood–brain barrier. Int. J. Pharm.379,285–292 (2009).
  Medline CASGoogle Scholar
• 32  Weiss CK, Kohnle MW, Landfester K et al. The first step into the brain: uptake of NIO-PBCA nanoparticles by endothelial cells in vitro and in vivo, and direct evidence for their blood–brain barrier permeation. ChemMedChem3,1395–1403 (2008).
  Medline CASGoogle Scholar
• 33  Petri B, Bootz A, Khalansky A et al. Chemotherapy of brain tumor using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate)nanoparticles: revisiting the role of surfactant. J. Control Release117,51–58 (2007).
  Medline CASGoogle Scholar
• 34  Gelperina S, Maksimenko O, Khalansky A et al. Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parameters. Eur. J. Pharm. Biopharm.74,157–163 (2010).▪ Extensive discussion of the characteristics of surfactants of nanoparticles necessary for their transport to the brain.
  Medline CASGoogle Scholar
• 35  Meijas R, Perez-Yagüe S, Roca AG et al. Liver and brain imaging through dimercaptosuccinic acid-coated iron oxide nanoparticles. Nanomedicine5,397–408 (2010).
  Google Scholar
• 36  Buyukhatipoglu K, Clyne AM. Superparamagnetic iron oxide nanoparticles change endothelial cell morphology and mechanics via reactive oxygen species formation. J. Biomed. Mater. Res.A96(1),186–195 (2011).
  MedlineGoogle Scholar
• 37  Apopa PL, Qian Y, Shao R et al. Iron oxide nanoparticles induce human microvascular endothelial cell permeability through reactive oxygen species production and microtubule remodeling. Part. Fibre Toxicol.6,1 (2009).
  MedlineGoogle Scholar
• 38  Soenen SJH, Himmelreich U, Nuytten N, De Cuyper M. Cytotoxic effect of iron oxide nanoparticles and implications for safety of cell labeling. Biomaterials32,195–205 (2011).
  Medline CASGoogle Scholar
• 39  Hekmatara T, Bernreuther C, Khalansky AS et al. Efficient systemic therapy of rat glioblastoma by nanoparticle-bound doxorubicin is due to antiangiogenic effects. Clin. Neuropathol.28,153–164 (2009).
  Medline CASGoogle Scholar
• 40  Gil ES, Li J, Lowe TL. Quarternary ammonium β-cyclodextrin nanoparticles for enhancing doxorubicin permeability across the in vitro blood–brain barrier. Biomacromolecues10,505–516 (2009).
  Medline CASGoogle Scholar
• 41  Ulbrich K, Hekmatara T, Herbert E, Kreuter J. Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood–brain barrier (BBB). Eur. J. Pharm. Biopharm.71,251–256 (2009).
  Medline CASGoogle Scholar
• 42  Zensi A, Begley D, Pontikis C et al. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurons. J. Control Release137,78–86 (2009).
  Medline CASGoogle Scholar
• 43  Zensi A, Begley D, Pontikis C et al. Human serum albumin nanoparticles modified with apolipoprotein A-I cross the blood–brain barrier and enter the rodent brain. J. Drug Target.18,842–848 (2010).
  Medline CASGoogle Scholar
• 44  Wagner S, Kufleitner J, Zensi A et al. Nanoparticulate transport of oximes over an in vitro blood–brain barrier model. PLoS ONE5,e14213 (2010).
  Medline CASGoogle Scholar
• 45  Cengelli F, Voinesco F, Juillerat-Jeanneret L. Interaction of cationic ultrasmall superparamagnetic iron oxide nanoparticles with human melanoma cells. Nanomedicine5,1075–1087 (2010).
  CASGoogle Scholar
• 46  Fiaux H, Kuntz DA, Hoffman D et al. Functionalized pyrrolidine inhibitors of human α-mannosidases II in cancer: optimizing the fit to the active site. Bioorg. Med. Chem.16,7337–7346 (2008).
  Medline CASGoogle Scholar
• 47  Lao F, Chen L, Li W et al. Fullerene nanoparticles selectively enter oxidation-damaged cerebral microvessel endothelial cells and inhibit JNK-related apoptosis. ACS Nano3,3358–3368 (2009).
  Medline CASGoogle Scholar
• 48  Liu HL, Hua MY, Yang HW et al. Magnetic resonance monitoring of focused ultrasound/magnetic nanoparticle targeting delivery of therapeutic agents to the brain. Proc. Natl Acad. Sci. USA107,15205–15210 (2010).▪ One of the first studies evaluating the use of magnetic field to deliver therapeutic nanoparticles to the brain.
  Medline CASGoogle Scholar
• 49  Wang ZH, Wang ZY, Sun CS, Wang CY, Jiang TY, Wang SL. Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain. Biomaterials31,908–915 (2010).
  Medline CASGoogle Scholar